Home › Funds › Trails Edge Capital Partners, LP › NRIX
Trails Edge Capital Partners, LP position in NRIX
NURIX THERAPEUTICS INC · Health Care
Trails Edge Capital Partners, LP reported holding 1,573,220 shares of NRIX (NURIX THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$38.2M, representing 6.06% of its reported portfolio and ranking #2 among its reported holdings. Trails Edge Capital Partners, LP has disclosed NRIX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Trails Edge Capital Partners, LP's NRIX position evolved
Trails Edge Capital Partners, LP first disclosed a stake in NRIX in Q4 2025 at 1,743,220 shares (US$33.1M). The position peaked in Q2 2026 at 1,573,220 shares, worth US$38.2M. Across 3 filings, Trails Edge Capital Partners, LP increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 1,573,220 shares valued at US$38.2M — a reduction of -170,000 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 1.74M | $33.07M | New |
| Q1 2026 | 1.74M | $27.02M | Hold |
| Q2 2026 | 1.57M | $38.17M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NRIX and 13F data
NRIX (NURIX THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in NRIX — the largest reported positions include Vestal Point Capital, LP (US$195.3M), Deep Track Capital, LP (US$187.7M), Rubric Capital Management LP (US$175.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NRIX
- Vestal Point Capital, LP 8.05M sh · $195.29M · Q2 2026
- Deep Track Capital, LP 7.74M sh · $187.69M · Q2 2026
- Rubric Capital Management LP 7.23M sh · $175.35M · Q2 2026
- BAKER BROS. ADVISORS LP 4.66M sh · $113.02M · Q2 2026
- PERCEPTIVE ADVISORS LLC 4.32M sh · $104.81M · Q2 2026
- Redmile Group, LLC 4.07M sh · $98.83M · Q2 2026
- GENERAL ATLANTIC, L.P. 3.03M sh · $73.56M · Q2 2026
- Soleus Capital Management, L.P. 1.47M sh · $35.54M · Q2 2026
- BRAIDWELL LP 1.29M sh · $31.22M · Q2 2026
- Kynam Capital Management, LP 1.19M sh · $28.98M · Q2 2026
- Affinity Asset Advisors, LLC 967.62K sh · $23.47M · Q2 2026
- Rhenman & Partners Asset Management AB 684.25K sh · $16.60M · Q2 2026
More on Trails Edge Capital Partners, LP
FAQ
How long has Trails Edge Capital Partners, LP held NRIX?
Trails Edge Capital Partners, LP has disclosed NRIX holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Trails Edge Capital Partners, LP's current position in NRIX?
As of Q2 2026, Trails Edge Capital Partners, LP holds 1.57M shares of NRIX (NURIX THERAPEUTICS INC), valued at $38.17M, representing 6.06% of its reported portfolio and ranking #2.
Has Trails Edge Capital Partners, LP been buying or selling NRIX?
In the latest 13F filing (Q2 2026), Trails Edge Capital Partners, LP reduced its position in NRIX. The position peaked in Q2 2026 at 1.57M shares.
Which other funds hold NRIX?
Other major institutional holders of NRIX include Vestal Point Capital, LP, Deep Track Capital, LP, Rubric Capital Management LP, among 46 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.